Results 81 to 90 of about 10,468 (295)

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, EarlyView.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source

Oral Hypoglycemic Agents [PDF]

, 1977
In conclusion, comment is made on the findings of the University Group Diabetes Program (UGDP). The purpose of the UGDP was to determine whether or not control of blood glucose levels would help to prevent or delay vascular disease in non-insulin ...
Rifkin, Harold
core   +1 more source

Pharmacogenetics in Type 2 Diabetes: Potential Implications for Clinical Practice [PDF]

, 2013
Pharmacogenetic research aims to study how genetic variation may influence drug efficacy and/or toxicity; pharmacogenomics expands this quest to the entire genome. Pharmacogenetic findings may help to uncover new drug targets, illuminate pathophysiology,
Florez, Jose Carlos, Huang, Chunmei
core   +1 more source

Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST‐3 study design

Diabetic Medicine, EarlyView.
Abstract Aims Lifestyle modification, including caloric restriction and exercise, is fundamental in the treatment of people living with overweight and type 2 diabetes mellitus (T2D). The overall aim of lifestyle intervention schemes is to reduce body weight and improve glycaemic control to reduce the future risk of diabetes‐associated complications ...
Caren Sourij, Alexander Müller, Abdullah Al‐Baghdadi, Faisal Aziz, Norbert J. Tripolt, Peter N. Pferschy, Eva Andritz, Harald Kojzar, Vanessa Stadlbauer, Sabrina Leal Garcia, Harald Sourij   +10 more
wiley   +1 more source

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial [PDF]

, 2009
Udgivelsesdato: 2009-OctAIMS/HYPOTHESIS: The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and ...
A. Vaag, B. K. Sethi, D. Russell-Jones, G. M. Ravn, M. Zdravkovic, N. Lalic, null null, O. Schmitz, R. Simó, S. Antic   +9 more
core   +2 more sources

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, EarlyView.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

Expert considerations to guide the development and delivery of an exercise intervention in people with type 2 diabetes‐related foot ulcer disease

Diabetic Medicine, EarlyView.
Abstract Objective Engaging in exercise presents unique challenges for those with type 2 diabetes (T2D) and diabetes‐related foot ulcer disease (DFUD). This brief report describes the development of practical considerations aiming to support exercise in people with T2D and DFUD.
Vicki L. Johnson, Vicky Hall, Rachel Berrington, Julia Burdon, Sally Schreder, Matthew McCarthy, Chris Brough, Patrick J. Highton, Michelle Hadjiconstantinou, Frances L. Game, Lisa J. Keogh, Solomon Tesfaye, Jonathan Valabhji, John R. Petrie, Ketan K. Dhatariya, Tom Yates, Melanie J. Davies, Kamlesh Khunti   +17 more
wiley   +1 more source

Changes in the Activity and Selectivity of Herbicides by Selective Fluorine Substitution, Taking Bentranil and Classic® Analogues as Examples

CHIMIA, 2004
The introduction of fluorine atoms into 2-phenyl-4H-3,1-benzoxazin-4-one (bentranil) led to sweeping changes in its herbicidal properties in some cases, and 5-fluoro-2-phenyl-4H-3,1-benzoxazin-4-one ('fluorobentranil') was found to be the most ...
Gerhard Hamprecht, Bruno Würzer, Matthias Witschel   +2 more
doaj   +1 more source

Cost‐Effectiveness of Control‐IQ+ Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE
Neda Al Rawashdh, Bimal V. Patel, Sharon M. Wang, Richard M. Zur, Pablo Anaya, Emily B. Kahn, Jordan E. Pinsker, Ravid Sasson‐Katchalski, Alex C. Trahan, Laurel H. Messer, Kimia Assadi, Yogish C. Kudva, Roy W. Beck   +12 more
wiley   +1 more source

Metabolomic insights into the intricate gut microbial–host interaction in the development of obesity and type 2 diabetes

Frontiers in Microbiology, 2015
Gut microbiota has recently been proposed as a crucial environmental factor in the development of metabolic diseases such as obesity and type 2 diabetes, mainly due to its contribution in the modulation of several processes including host energy ...
Magali ePalau-Rodriguez, Sara eTulipani, Sara eTulipani, MARIA ISABEL MI QUEIPO ORTUÑO, Mireia eUrpi-Sarda, Francisco J Tinahones, Cristina eAndres-Lacueva   +6 more
doaj   +1 more source